Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) EPS (Basic) (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed EPS (Basic) for 15 consecutive years, with -$0.54 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Basic) rose 22.86% year-over-year to -$0.54, compared with a TTM value of -$2.3 through Sep 2025, up 68.75%, and an annual FY2024 reading of -$2.92, up 86.71% over the prior year.
  • EPS (Basic) was -$0.54 for Q3 2025 at Alaunos Therapeutics, up from -$0.63 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.04 in Q2 2022 and bottomed at -$11.15 in Q2 2023.
  • Average EPS (Basic) over 5 years is -$1.56, with a median of -$0.63 recorded in 2023.
  • The sharpest move saw EPS (Basic) crashed 27775.0% in 2023, then soared 93.63% in 2024.
  • Year by year, EPS (Basic) stood at -$0.06 in 2021, then tumbled by 4033.33% to -$2.48 in 2022, then crashed by 97.58% to -$4.9 in 2023, then soared by 90.61% to -$0.46 in 2024, then dropped by 17.39% to -$0.54 in 2025.
  • Business Quant data shows EPS (Basic) for TCRT at -$0.54 in Q3 2025, -$0.63 in Q2 2025, and -$0.67 in Q1 2025.